

The Saccadic System: A Neurological Microcosm

Familiarity can breed contempt: perhaps it is precisely because the saccade is the commonest movement we make – about three every second of our waking lives – that we rather take it for granted. Yet, apart from being a movement of extraordinary speed and elegant precision^{1,2} (fig. 1), it not only determines absolutely what we are allowed to see, but precedes and prepares for nearly every directed action that we make. Research over the last couple of decades has demonstrated in detail the involvement in saccadic control of nearly every level of the brain, from the simple neural circuits in the brainstem reticular formation that ensure the saccade's remarkable technical performance, to neurons in frontal eye fields that help decide whether to look at one thing or another^{3,4}. As a result we have a more detailed understanding of the saccadic system, in the sense of being able to relate structure and disorder of structure to quantitative measurements of function, than of any other sub-system of the brain. Because saccades are stereotyped movements, small deviations may carry immense clinical significance. As a result, recent technical advances (in making micro-miniaturised oculometers that store data for subsequent analysis by lap-top) have begun to turn this neurophysiological knowledge into clinical utility, inaugurating what may perhaps turn out to be a new era of genuinely *quantitative* neurology⁵.

The saccadic hierarchy

There is an intrinsic three-fold hierarchy in any motor act, that can be summarised as *what, where, how*: recognition of a target, and decision; localisation and proprioception; and creation of the detailed patterns of forces needed for execution. This general principle of motor organisation is particularly clearly seen in the saccadic system^{2,3} (fig. 2). At the lowest level are the neural circuits in the prepontine and mesencephalic reticular formation, close to the oculomotor nuclei, that generate the highly specific temporal patterns of firing by which the oculomotor neurons move the eye so precisely and rapidly to their new position. Above them, the colliculus primarily has the task of converting information about the visual location of an object into an appropriate command to the brainstem that will move the gaze to the same location; in this it is supplemented by the cerebellum and has assistance from the cortex. But in the real world we are seldom

presented with just a single potential target: we must choose between many, and some will have more significance than others. This choice – deciding what to look at – is a function that culminates specifically in the frontal eye fields. All of these hierarchical levels have immense diagnostic potential; for instance, saccadic slowing characteristic of disorder at the lowest level may be a very early indicator of neurodegeneration⁶. But in this review there is only space to concentrate on the highest level, where recent work has used the stereotyped precision of saccades to discover a great deal about how cortical areas make saccadic decisions^{7,8}.

Latency: the measurement of decision

The two lowest levels of the saccadic hierarchy are in principle all that is needed to generate a saccade that lands accurately and swiftly on a visual target. In a laboratory situation, with single targets presented in the dark, that would be fine. But the real world is full of interesting stimuli competing for our attention. While the collicular level can localise visual targets, what it cannot do is *recognise* them, or evaluate their behavioural significance, for which the cortex appears to be necessary. Consequently, we find that the collicular mechanisms are tonically switched off by descending, ultimately cortical, inhibition, and only permitted to carry out their function when the higher processes of decision are complete. As a result, we have *procrastination*. The time between presenting a stimulus and starting to make a response – the saccadic latency – is far longer than would be expected from the speed of visual transduction, nerve conduction and synaptic action. Reaction time is decision time, and studies of how this latency varies with changing stimuli and circumstances – and in neurological disorder – have yielded much information about how these decision mechanisms work. The result is something called the LATER model: as well as recalling the procrastination the name stands for Linear Approach to Threshold with Ergodic Rate. This succinct but perhaps cryptic expression implies the existence of decision units, whose activity represents the system's degree of belief in different possible targets; at rest, their activity represents prior probability or expectation, and as sensory evidence comes that supports the belief, their activity increases linearly until it reaches a threshold, the point where it is so overwhelm-



Roger Carpenter is Reader in Oculomotor Physiology at Cambridge University, and the author of the popular text-book *Neurophysiology* as well as many papers on higher aspects of saccadic control. For many years he has been Director of Medical Studies at Gonville and Caius College, and in 2000 was one of the inaugural group of twenty winners of £50,000 national teaching awards from the ILTE.




Figure 1. A set of seven human saccades evoked by sudden movement of a target 15 deg to the left, showing that although these very stereotyped movements are rapid in the sense that the velocity of the eye is many hundreds of degrees per second, there is a long latency before the movement starts at all, that varies randomly from trial to trial.




Figure 2. The saccadic hierarchy. At the highest level, a target must be recognised and a decision made as to whether it is worth looking at; this decision gates the intermediate level, at which information about the target's location is translated into selection of an appropriate saccadic metric; and this in turn activates brainstem circuitry that elaborates the complex patterns of neural firing that throw the gaze efficiently and rapidly on to the target, as in figure 1.

UK ABBREVIATED PRESCRIBING INFORMATION: PROVIGIL® 100 mg/200 mg Tablets

Please refer to UK Summary of Product Characteristics (SmPC) before prescribing. **Presentation:** White to off-white tablets containing modafinil 100 mg or modafinil 200 mg (indicated by '100' or '200' debossed on one side). **Indication:** Excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnoea/hypopnoea syndrome. **Dosage:** Adults: 200–400 mg daily either as two divided doses in the morning and at noon or as a single morning dose according to response. **Elderly:** Treatment should start at 100 mg daily, which may be increased subsequently to the maximum adult daily dose in the absence of renal or hepatic impairment. **Severe renal or hepatic impairment:** Reduce dose by half (100–200 mg daily). **Children:** See contra-indications. **Contra-indications:** Use in pregnancy and lactation, children, uncontrolled moderate to severe hypertension, arrhythmia, hypersensitivity to modafinil or any excipients used in Provigil. **Warnings and precautions:** Patients with major anxiety should only receive Provigil treatment in a specialist unit. Sexually active women of child-bearing potential should be established on a contraceptive programme before taking Provigil. Blood pressure and heart rate should be monitored in hypertensive patients. In patients with obstructive sleep apnoea, the underlying condition (and any associated cardiovascular pathology) should be monitored. Provigil is not recommended in patients with a history of left ventricular hypertrophy nor in patients who have experienced mitral valve prolapse syndrome when previously receiving CNS stimulants. This syndrome may present with ischaemic ECG changes, chest pain or arrhythmia. Studies of modafinil have demonstrated a low potential for dependence, although the possibility of this occurring with long-term use cannot be entirely excluded. **Drug interactions:** Modafinil is known to induce CYP3A4/5 (and to a lesser extent, other) enzymes and so may cause clinically significant effects on other drugs metabolised via the same pathways. The effectiveness of oral contraceptives may be impaired through this mechanism. When these are used for contraception, a product containing at least 50 mcg ethinylestradiol should be taken. Certain tricyclic antidepressants and selective serotonin reuptake inhibitors are largely metabolised by CYP2D6. In patients deficient in CYP2D6 (approximately 10% of the population) a normally ancillary metabolic pathway involving CYP2C19 becomes more important. As modafinil may inhibit CYP2C19 lower doses of antidepressants may be required in such patients. Care should also be observed with co-administration of other drugs with a narrow therapeutic window, such as anti-convulsant or anticoagulant drugs. **Side effects:** Very common (>10%) – headache, nervousness. Common (>1%) – insomnia, anxiety, dizziness, somnolence, depression, abnormal thinking, confusion, paraesthesia, hypertension, nausea, dry mouth, diarrhoea, decreased appetite, dyspepsia, constipation, tachycardia, palpitation, vasodilatation, asthenia, chest pain, abdominal pain and blurred vision. Dose related increases in alkaline phosphatase and gamma glutamyl transferase have been observed. (See SmPC for uncommon side effects). **Basic NHS Cost:** Pack of 30 blister packed 100 mg tablets: £60.00. Pack of 30 blister packed 200 mg tablets: £120.00. **Marketing authorisation numbers:** PL 16260/0001 Provigil 100 mg Tablets, PL 16260/0002 Provigil 200 mg Tablets. **Marketing authorisation holder:** Cephalon UK Limited. **Legal category:** POM. **Date of preparation:** September 2003. Provigil and Cephalon are registered trademarks. Full prescribing information, including SmPC, is available from **Cephalon UK Limited**, 11/13 Frederick Sanger Road, Surrey Research Park, Guildford, Surrey GU2 7YD, Medical Information Freefone 0800 783 4869 (ukmedinfo@cephalon.com).

References:

- Young T et al. *N Engl J Med* 1993; **328**: 1230-1235.
- Sforza E and Krieger J. *J Neurol Sci* 1992; **110**: 21-26.
- Guilleminault C and Philip P. *Sleep* 1996; **19**(9): S117-S122.
- Strollo PJ et al. *N Engl J Med* 1996; **334**: 99-104.
- Bedard M-A et al. *J Clin Exp Neuropsychol* 1993; **15**: 330-341.
- Kales A et al. *J Chron Dis* 1985; **38**(5): 427-434.
- US Modafinil in Narcolepsy Multicenter Study Group. *Neurology* 2000; **54**: 1166-1175.
- US Modafinil in Narcolepsy Multicenter Study Group. *Ann Neurol* 1998; **43**: 88-97.
- Broughton RJ et al. *Neurology* 1997; **49**: 441-451.
- Hirshkowitz M et al. *Sleep* 2001; **24** (Ab Suppl): A239.
- Provigil in OSAHS Study Group (5545).



© Cephalon UK Limited, 11/13 Frederick Sanger Road, Surrey Research Park, Guildford, Surrey GU2 7YD. All rights reserved. September 2003.

PRO739/Sept 03




Figure 3.

A miniature, non-invasive saccadometer in use. In this prototype, stimuli are projected on to a convenient surface by the three miniature lasers at the top; a system of infra-red emitters and detectors monitors the ensuing saccades, the information being analysed and stored in a separate, tiny microprocessor unit which can subsequently communicate with the user's computer through an infra-red link.

ingly probable that action is justified, and initiated⁹. Such a system can be regarded as an 'ideal' decision device, in the sense that it makes maximal use of information to alter its estimated probabilities through an essentially Bayesian mechanism.

LATER seems to be applicable to all reaction times, whether saccadic or manual, and inaugurated by visual or auditory or even tactile stimuli, and provides quantitative predictions of what happens when expectations alter, when information is only partially available, or when a subject is under pressure to respond more urgently¹⁰. A well-known feature of latency is that it varies randomly from trial to trial, and this randomness seems to be created 'deliberately' by the brain. Because many such units, corresponding to different possible actions, normally race against one another, the winner determining the response that is finally selected, this randomness in timing results in randomness of choice, perhaps in order to make our behaviour unpredictable, and

References

- Becker, W. (1992). *Saccades*. In *Eye Movements*. ed. Carpenter, R.H.S., pp. 95-137. MacMillan, London.
- Carpenter, R.H.S. (2000). *The neural control of looking*. *Current Biology* 10, 291-293.
- Munoz, D.P. (2002). *Commentary: Saccadic eye movements: overview of neural circuitry*. *Progress in Brain Research* 140, 89-96.
- Carpenter, R.H.S. (1988). *Movements of the Eyes*. Pion, London.
- Leigh, R.J. and Zee, D.S. (1999). *The neurology of eye movements*. Oxford University Press, New York.
- Zarei, M., Nouraei, S.A.R., Caine, D., Hodges, J.R. & Carpenter, R.H.S. (2002). *Neuropsychological and quantitative oculometric study of a case of sporadic Creutzfeldt-Jakob disease at pre-dementia stage*. *Journal of Neurology, Neurosurgery and Psychiatry* 73, 56-58.
- Schall, J.D. (2000). *Decision making: from sensory evidence to a motor command*. *Current Biology* 10, 404-406.
- Schall, J.D., Stuphorn, V. & Brown, J.W. (2002). *Monitoring and control of action by the frontal lobes*. *Neuron* 36, 309-322.
- Carpenter, R. H. S. & Williams, M.L.L. (1995). *Neural computation of log likelihood in the control of saccadic eye movements*. *Nature* 377, 59-62.
- Reddi, B.A.J., Asrress, K.N. & Carpenter, R.H.S. (2003). *Accuracy, information and response time in a saccadic decision task*. *Journal of Neurophysiology* 90, 3538-3546.
- Leach, J.C.D. and Carpenter, R.H.S. (2001). *Saccadic choice with asynchronous targets: evidence for independent randomisation*. *Vision Research* 41, 3437-3445.
- Carpenter, R.H.S. (1999). *A neural mechanism that randomises behaviour*. *Journal of Consciousness Studies* 6, 13-22.
- Hanes, D. P. and Schall, J.D. (1996). *Neural control of voluntary movement initiation*. *Science* 274, 427-430.
- Kobayashi, Y., Saito, Y. & Tadashi, I. (2001). *Facilitation of saccadic initiation by brainstem cholinergic system*. *Brain Development* 23, 524-527.
- Robbins, T.W. (2000). *Chemical neuro-modulation of frontal executive functions in humans and other animals*. *Experimental Brain Research* 133, 130-138.

perhaps also to generate exploration and creativity^{11,12}.

Recordings from the frontal eye fields in monkeys have revealed a population of saccadic movement-related neurons whose activity is very similar to what was predicted by LATER¹³. Before a saccade, firing frequency rises steadily for 100-200 msec before the start of a saccade, the movement being initiated when the activity reaches a fixed threshold level; the rate of rise varies randomly from trial, in correspondence with the variability in the latency itself. LATER-like rise-to-threshold behaviour can be seen in many areas of the cortex in advance of motor responses, and may well represent something quite fundamental about how the cortex works.

Future developments

An attractive aspect of LATER is that the performance of the eye in terms of latency can be summarised essentially by just two numbers, which are in turn directly related to the parameters of the model itself. They represent the fundamental parameters that must be defined for any decision system: for example, whether speed is more important than accuracy, the relative weight to be attached to present rather than past information, and the degree of creativity (randomness). In the brain, these parameters clearly need to be regulated in some way, and an exciting possibility is that they might possibly be related to the several ascending systems – noradrenergic, serotonergic, histaminergic – that innervate cortex relatively diffusely from below^{14,15}. The reason for having so many has always been a puzzle: if all they do is cause 'arousal' one would surely be enough. We hope soon to be able to establish whether defects in these systems do indeed cause the quantitative changes that LATER would predict. If so, the fact that miniature non-invasive devices for measuring eye movements (fig. 3), requiring practically no skill in setting up, will very soon be available at little cost and could revolutionise the diagnosis and monitoring of neurological impairment.



For a case report on vertical supranuclear gaze palsy, see <http://acnr.co.uk/case%20report.htm>

Correspondence Address:

R H S Carpenter, The Physiological Laboratory, University of Cambridge, CB2 3EG UK. E-Mail: rhsc1@cam.ac.uk